Tibulizumab 产品活性：Tibulizumab (LY 3090106) 是一种四价双特异性单克隆抗体，靶向 B 细胞激活因子 (BAFF) 和 IL-17A，Kd 值分别为 60 pM 和 14 pM。 Tibulizumab 可用于自身免疫性疾病研究。 产品来源： https://www.medchemexpress.cn/tibulizumab.html 研究领域：Apoptosis | Immunology/Inflammation 作用靶点：TNF Receptor | Interleukin Related In Vitro: Tibulizumab (LY 3090106) binds to mouse BAFF with a KD of 340 nM and does not bind to mouse IL-17. Tibulizumab binds to cynomolgus BAFF and cynomolgus IL-17 with KD of 26.8 pM and 19 pM, respectively. In HT-29 cells, Tibulizumab antagonizes the IL-17-induced secretion of CXCL1 in a concentration-dependent manner (IC50 of 2.00 nM). In T1165 cells, Tibulizumab blocks BAFF-induced proliferation in a concentration-dependent manner (IC50 of 0.064 nM). Tibulizumab simultaneously binds and blocks both BAFF and IL-17. In Vivo: Tibulizumab (LY 3090106; 660 µg/mouse, i.p; 66 µg/mouse, s.c) effectively antagonizes the biological effects induced by human BAFF and IL-17 in the mouse. In cynomolgus monkey, Tibulizumab (i.v, 0.3, 1, 5, or 20 mg/kg; or s.c, 5 mg/kg) suppresses B cell development and survival and remains functionally intact in circulation, with a prolonged half-life. 相关产品：Resatorvid | Disulfiram | Polyinosinic-polycytidylic acid | Raleukin | Deucravacitinib | Shikonin | Infliximab | Dupilumab | Tocilizumab | Apilimod | Fisetin | Oxidopamine hydrobromide | Adalimumab | Etanercept | N-Formyl-Met-Leu-Phe | LMT-28 | Apremilast | R-7050 | Theophylline | QNZ | Secukinumab | Nafamostat mesylate | Clofazimine | C25-140 | Sodium metatungstate | Diprovocim | Benzbromarone | UCB-9260 | SC144 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。